Skip to content

Author

M. Camilli

We have 3 of 115 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Rationale and Design of the CARdio-Tox Study: A Prospective Evaluation of Cardiovascular Toxicity in Patients Receiving Chimeric Antigen Receptor-T (CAR-T) Cell Therapy.

Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as an innovative treatment of haematologic malignancies; however, its use is frequently complicated by Cytokine Release Syndrome (CRS), an increasingly recognized driver of cancer therapy-related cardiovascular toxicity (CTR-CVT) able to provoke a wide spectrum...

M. Camilli, M. Ortenzi, L. Leo et al. · 0 citations
Review Aug 2026

Sacubitril/valsartan in anthracycline-treated patients: a systematic review and meta-analysis of available evidence

A consistent, hypothesis-generating signal is identified suggesting that sacubitril/valsartan may reduce CTRCD incidence and favorably influence cardiac imaging parameters in anthracycline-treated patients, at the cost of increased symptomatic hypotension.

M. Camilli, L. Spadafora · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.